Epidemiologic studies suggest that the risk for AMD is increased in women undergoing menopause and that women on hormone-replacement therapy have a reduced risk of having the disease.
10,11 Several in vitro studies have shown that estradiol (E
2) prevents oxidative stress–induced apoptosis of retinal neurons,
12 RPE cells,
13 and human lens epithelial cells (HLECs).
14 Despite the promising results, the use of 17β-E
2 to treat oxidative stress in the retina has been limited because of severe side effects that include increased risk of cardiovascular disease and uterine cancer.
15,16 Estradiol binds with high affinity to estrogen receptor (ER)-α and -β, which are expressed in multiple tissues, thus causing pleiotropic effects. Most of the estrogenic responses in tissues are associated with the activation of ERα, whereas ERβ appears to act as a negative regulator of ERα.
17 We demonstrated in a prior study that 17β-E
2 protects RPE cells from oxidative stress in an ERβ-dependent manner, suggesting that ERβ-selective agonists could be beneficial for prevention of oxidative stress.
13 In this article, we explore the mechanism of RPE protection by one such agonist, GTx-822 (GTx, Inc., Memphis, TN), which has a selectivity for ERβ over that for ERα. This study is the first to demonstrate that an ERβ-selective agonist can protect RPE from oxidative stress and cell death. Pharmacologic antagonism of ERβ reversed the protective effects of GTx-822. Further, ERβ–GTx-822 interaction mediated cytoprotection through the activation of cell survival protein kinases: PI3-K, Akt, ERK1/2, and RSK. Activation of these pathways phosphorylated Bad (a proapoptosis protein), thereby preventing its translocation to the mitochondria and thus inhibiting cell death.